U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C10H16NO.Cl
Molecular Weight 201.693
Optical Activity NONE
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EDROPHONIUM CHLORIDE

SMILES

[Cl-].CC[N+](C)(C)C1=CC=CC(O)=C1

InChI

InChIKey=BXKDSDJJOVIHMX-UHFFFAOYSA-N
InChI=1S/C10H15NO.ClH/c1-4-11(2,3)9-6-5-7-10(12)8-9;/h5-8H,4H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula C10H15NO
Molecular Weight 165.2322
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

Originator

Curator's Comment: reference retrieved from http://www.drugfuture.com/chemdata/edrophonium-chloride.html # Hoffmann La Roche

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
ENLON

Approved Use

Enlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

Launch Date

1985
Preventing
ENLON

Approved Use

Enlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

Launch Date

1985
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
84.2 min
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
56.6 min
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
110 min
0.5 mg/kg single, intravenous
dose: 0.5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
110 min
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Determination of inhibitors' potency (IC50) by a direct high-performance liquid chromatographic method on an immobilised acetylcholinesterase column.
2001 Apr 5
Electrogastrography: a non-invasive measurement of gastric function.
2001 Apr-Jun
Edrophonium antagonism of cisatracurium-induced neuromuscular block: dose requirements in children and adults.
2001 Aug
Asystole induced by edrophonium following beta blockade.
2001 Aug 28
Reversal of rocuronium with edrophonium during propofol versus sevoflurane anesthesia.
2001 Feb
A dose-response study of anticholinesterase drugs on contractile and phosphatidylinositol responses of rat trachea.
2001 Jan
[Voice disorders caused by neurological diseases].
2001 Jul 16-31
Thioflavin T is a fluorescent probe of the acetylcholinesterase peripheral site that reveals conformational interactions between the peripheral and acylation sites.
2001 Jun 29
[Giant-cell myocarditis without a symptom of heart failure seen in a patient with myasthenia gravis and concurrent Hashimoto's disease].
2001 Nov
Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampus.
2001 Oct 1
Respiratory failure due to vocal cord paresis in myasthenia gravis.
2002
Clinical, electrophysiological and immunological remissions after thymectomy in myasthenia gravis.
2002 Apr
Autosomal recessive limb girdle myasthenia in two sisters.
2002 Dec
[Seronegative myasthenia gravis].
2002 Jan
Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.
2002 Nov
[Comparison between idiopathic achalasia and achalasia caused by Chagas' disease: a review on the publications about the subject].
2003 Apr-Jun
Ocular myasthenia gravis associated with euthyroid ophthalmopathy.
2003 Dec
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
2003 Feb
beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies.
2003 Feb 1
Edrophonium effectively antagonizes neuromuscular block at the laryngeal adductors induced by rapacuronium, rocuronium and cisatracurium, but not mivacurium.
2003 Nov
[Response to thymectomy in patients with thymoma].
2003 Nov-Dec
Interactions of edrophonium with neostigmine in the rat trachea.
2003 Oct
Antinociception of intrathecal cholinesterase inhibitors and cholinergic receptors in rats.
2003 Oct
Myasthenia gravis in childhood.
2004
Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome.
2004 Apr 13
Appearance of systemic lupus erythematosus in patients with myasthenia gravis following thymectomy: two case reports.
2004 Feb
Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients.
2004 Mar
A case of Lambert-Eaton myasthenic syndrome associated with atypical bronchopulmonary carcinoid tumor.
2004 Oct
Evaluation of mechanisms of azinphos-methyl resistance in the codling moth Cydia pomonella (L.).
2004 Oct
Painful sweating.
2004 Oct 26
Pupil-sparing, painless compression of the oculomotor nerve by expanding basilar artery aneurysm: a case of ocular pseudomyasthenia.
2004 Sep
Advances in the diagnosis of neuromuscular junction disorders.
2005 Aug
Postinfectious myasthenia gravis: report of two children.
2005 May
Patents

Sample Use Guides

In Vivo Use Guide
Enlon (edrophonium injection) ® Test in the Differential Diagnosis of Myasthenia Gravis:1-8 Intravenous Dosage (Adults): A tuberculin syringe containing 1 mL (10 mg) of Enlon (edrophonium injection) ® is prepared with an intravenous needle, and 0.2 mL (2 mg) is injected intravenously within 15 to 30 seconds. The needle is left in situ. Only if no reaction occurs after 45 seconds is the remaining 0.8 mL (8 mg) injected. If a cholinergic reaction (muscarinic side effects, skeletal muscle fasciculations and increased muscle weakness) occurs after injection of 0.2 mL (2 mg), the test is discontinued and atropine sulfate, 0.4 mg to 0.5 mg, is administered intravenously. After one-half hour the test may be repeated. Intramuscular Dosage (Adults): In adults with inaccessible veins, dosage for intramuscular injection is 1 mL (10 mg) of Enlon (edrophonium injection) ®. Subjects who demonstrate hyperreactivity to this injection (cholinergic reaction), should be retested after one-half hour with 0.2 mL (2mg) of Enlon (edrophonium injection) ® intramuscularly to rule out false-negative reactions. For Use as a Curare Antagonist: Enlon (edrophonium injection) ® should be administered by intravenous injection in 1 mL (10 mg) doses given slowly over a period of 30 to 45 seconds so that the onset of cholinergic reaction can be detected. This dosage may be repeated whenever necessary. The maximal dose for any one patient should be 4 mL (40 mg). Because of its brief effect, Enlon (edrophonium injection) ® should not be given prior to the administration of curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine: it should be used at the time when its effect is needed. When given to counteract curare overdosage, the effect of each dose on the respiration should be carefully observed before it is repeated, and assisted ventilation should always be employed.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:30:10 GMT 2025
Edited
by admin
on Wed Apr 02 07:30:10 GMT 2025
Record UNII
QO611KSM5P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ENLON-PLUS COMPONENT EDROPHONIUM CHLORIDE
Preferred Name English
EDROPHONIUM CHLORIDE
EP   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
ENLON
Brand Name English
EDROPHONIUM CHLORIDE [USP-RS]
Common Name English
EDROPHONIUM CHLORIDE [USP MONOGRAPH]
Common Name English
EDROPHONIUM CHLORIDE [EP MONOGRAPH]
Common Name English
EDROPHONIUM CHLORIDE [MI]
Common Name English
Edrophonium chloride [WHO-DD]
Common Name English
EDROPHONIUM CHLORIDE [JAN]
Common Name English
NSC-759577
Code English
EDROPHONIUM CHLORIDE [VANDF]
Common Name English
EDROPHONIUM CHLORIDE [ORANGE BOOK]
Common Name English
EDROPHONIUM CHLORIDE [WHO-IP]
Common Name English
BENZENAMINIUM, N-ETHYL-3-HYDROXY-N,N-DIMETHYL-, CHLORIDE
Systematic Name English
edrophonium chloride [INN]
Common Name English
ETHYL(M-HYDROXYPHENYL)DIMETHYLAMMONIUM CHLORIDE
Systematic Name English
EDROPHONIUM CHLORIDE [MART.]
Common Name English
TENSILON
Brand Name English
ANTIREX
Common Name English
REVERSOL
Brand Name English
EDROPHONII CHLORIDUM [WHO-IP LATIN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C47792
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C47507
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
EPA CompTox
DTXSID1022978
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
CHEBI
4759
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
SMS_ID
100000080513
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
DRUG BANK
DBSALT000475
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
INN
187
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
EDROPHONIUM CHLORIDE
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY Description: A white, crystalline powder; odourless.Solubility: Soluble in 0.5 parts of water and in 5 parts of ethanol (~750 g/l) TS; practically insoluble in ether R.Category: Diagnostic agent.Storage: Edrophonium chloride should be kept in a well-closed container, protected from light.Requirements: Definition. Edrophonium chloride contains not less than 98.5% and not more than 101.0% of C10H16ClNO, calculated withreference to the dried substance.
ECHA (EC/EINECS)
204-138-4
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
FDA UNII
QO611KSM5P
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
ChEMBL
CHEMBL1104
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
CAS
116-38-1
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
RS_ITEM_NUM
1234001
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
MERCK INDEX
m4834
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY Merck Index
PUBCHEM
8307
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
EVMPD
SUB06461MIG
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
NSC
759577
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
DAILYMED
QO611KSM5P
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY
RXCUI
3754
Created by admin on Wed Apr 02 07:30:10 GMT 2025 , Edited by admin on Wed Apr 02 07:30:10 GMT 2025
PRIMARY RxNorm
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY